SeraCare Life Sciences has launched what it claims to be the first commercially available anti-dengue mixed titer performance panel. This addition to the company’s line of infectious disease panels responds to growing demand for accurate testing for dengue virus, which infects an estimated 50 to 100 million people annually, according to the World Health Organization.
The performance panel is designed to help blood-donor collection facilities, diagnostics manufacturers and clinical laboratories evaluate and troubleshoot their anti-dengue virus assays. It is derived from undiluted, unpreserved human plasma specimens, with 21 members representing a wide range of reactivity for anti-dengue IgM and IgG antibodies, from negative to strongly positive. Panel members include samples from individuals with recent and past infection by all four dengue viruses (DENV-1 through DENV-4).
Phone: 07 3386 7999
Mercodia Insulin MBeads Assay
The assay is designed to offer high accuracy by specifically measuring human insulin while...
Waters BD FACSDiscover A7 Cell Analyzer
The BD FACSDiscover A7 Cell Analyzer combines high spectral resolution and sensitivity with...
Lumiprobe CytoTracer fluorescent cell dyes
The dyes rapidly penetrate cells, form intracellular membrane-impermeable products, and deliver...
